HidraMed Solutions is proud to announce our sponsorship of the newly published International Consensus Document on Best Practice in the Management of Hidradenitis Suppurativa (HS) Lesions, now featured in the Journal of Wound Care.
Hidradenitis Suppurativa is a painful, chronic inflammatory skin condition that affects approximately 1% of the population. HS lesions can cause severe pain, significant exudate, and malodour, often leading to profound physical, emotional, and social impacts.
Despite the availability of general treatment guidelines, targeted guidance for the local management of HS wounds has remained a critical gap, until now.
This landmark publication is the first of its kind to focus specifically on lesional management, a critical, often overlooked area in HS care.
Developed by a global panel of dermatologists, wound care specialists, nurses, and surgeons, it provides comprehensive, multidisciplinary guidance and tools. This includes evidence-led guidance covering:
- HS lesion pathophysiology, bacterial burden, and perilesional skin damage
- Impact of HS on patients’ psychological, practical, and socioeconomic well-being
- Diagnosis, assessment tools, and streamlined referral pathways
- Medical, surgical, and lesional management strategies
- Education initiatives for both clinicians and patients
Among its aims, the document wants to improve the management of HS lesions. Lesional pain, exudate and malodour are typically the main drivers of poor quality of life in HS and thus require prompt and effective relief. This can be achieved by prioritising access to specialist wound care for lesional management, including antimicrobial cleansing and absorptive dressings, as well as interventions to resolve irritant contact dermatitis and MARSI.
By offering a standardised and evidence-informed care pathway, the consensus aims to reduce delays in treatment, enhance symptom management, and empower patients through better education and support.
“At HidraMed Solutions, we are committed to improving the lives of those affected by HS through both innovative products and advocacy for evidence-based care,” said Suzanne Moloney, HidraMed CEO & Founder. “We’re honoured to support this much-needed initiative that offers clinicians practical guidance and patients real hope.”
The document provides a vital resource for clinicians across disciplines, including dermatology, wound care, nursing, and primary care, seeking to enhance the quality, consistency, and compassion of care delivered to HS patients.
Access the full consensus document here:
👉 Download the International Consensus on HS Lesion Management
